<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>PSM-(INICET NOV 2024)</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`üß† Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">PSM-(INICET NOV 2024)</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                17 Questions | 17 Total Marks | 27 min Duration | ~95.29 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 17 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 27 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 17</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">PSM-(INICET NOV 2024) - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 17</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 17 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "Which is not a part of Anemia Mukt Bharat Programme?", "options": [{"label": "A", "text": "6 beneficiaries", "correct": false}, {"label": "B", "text": "6 interventions", "correct": false}, {"label": "C", "text": "6 institutional mechanisms", "correct": false}, {"label": "D", "text": "6 health functionaries", "correct": true}], "correct_answer": "D. 6 health functionaries", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>6 health functionaries The Anemia Mukt Bharat Programme is a national initiative aimed at reducing anemia in India. It employs a 6x6x6 strategy, focusing on six beneficiary groups (children, adolescents, pregnant and lactating women), six interventions (iron supplementation, deworming, behavior change communication, etc.), and six institutional mechanisms for effective implementation.</p>\n<p><strong>Highyeild:</strong></p><p>The Anemia Mukt Bharat program is a comprehensive and multi-pronged approach to address the problem of anemia in India. By focusing on early detection, prevention, and management, the program aims to improve the health and well-being of millions of women and children. Objectives: Reduce prevalence of anemia among pregnant women and children (6-59 months) to less than 5% by 2030. Ensure early detection and management of anemia through screening and testing. Promote preventive measures to address the root causes of anemia. Key interventions: Intensified Iron Folic Acid Supplementation (IFA) program for pregnant women and children. Deworming tablets for children. Behaviour change communication activities to promote dietary diversification and healthy practices. Integration with other health programs such as the National Health Mission (NHM) and the Anganwadi program. Monitoring and evaluation: Regular monitoring of program implementation and coverage. Conduct of anemia surveys to track progress. Evaluation of the impact of the program on anemia prevalence and related outcomes. Key stakeholders: Ministry of Health and Family Welfare (MoHFW) State health departments Implementing agencies such as UNICEF, WHO, and NGOs Communities and beneficiaries</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. 6 beneficiary groups: Children (6-59 months), children (5-9 years), adolescents (10-19 years), pregnant women, lactating women, and women of reproductive age group (15-49 years). Option: B. 6 interventions: Prophylactic Iron Folic Acid Supplementation, Periodic Deworming, Intensified Year-Round Behavior Change Communication, Delayed Cord Clamping, Increased Testing and Treatment of Anemia, and Fortification of Foods. Option: C. 6 institutional mechanisms: A robust institutional mechanism at the national, state, and district levels to ensure effective implementation of the program.</p>\n<p><strong>Table:</strong></p><p>#MANTRA IFA supplementation for different age groups: Age group Iron dose Folic Acid dose Timing Color Remarks Children 6-59 months of age 20 mg Iron 100 mcg Bi weekly Liquid bottle with auto dispenser Children 5-9 years of age 45 mg 400 mcg Weekly Pink color Sugar coated School-going Adolescent Girls and Boys, 10-19 years of age Out-of-school Adolescent Girls, 10-19 years of age 60 mg 500 mcg Weekly Blue color Sugar coated Women of Reproductive Age (non-pregnant, non-lactating) 20-49 years (Under Mission Parivar Vikas) 60 mg 500 mcg Weekly Red color Sugar coated Pregnant Women and Lactating Mothers (of 0-6 months child) 60 mg 500 mcg Daily Red color Sugar coated</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "You have gone to a village for screening where people have diabetes and hypertension. What type of screening is done for family members of these patients who show up in large numbers?", "options": [{"label": "A", "text": "Multiphasic screening", "correct": false}, {"label": "B", "text": "Mass screening", "correct": false}, {"label": "C", "text": "High-risk screening", "correct": true}, {"label": "D", "text": "Anonymous screening", "correct": false}], "correct_answer": "C. High-risk screening", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>High-risk screening High-risk screening is conducted for family members of patients with conditions like diabetes and hypertension. Since these individuals are at a higher risk of developing the same conditions due to genetic or environmental factors, screening focuses on identifying those at higher risk rather than screening the entire population. This approach is more efficient and targeted compared to mass or multiphasic screening.</p>\n<p><strong>Highyeild:</strong></p><p>Screening is a process of identifying individuals in a population who are at risk of a particular disease or condition, or who may already have it, but do not yet show symptoms. The goal of screening is to detect diseases at an early stage, when they are more treatable, and to prevent further complications. Mass screening refers to screening the entire population or large groups of people, regardless of their risk factors, to detect certain diseases early. This approach is typically used for conditions with high prevalence and for which early detection leads to better outcomes, such as newborn screening for metabolic disorders. High-risk (or selective/targeted) screening focuses on individuals who are at greater risk of developing a specific disease, such as family members of individuals with hypertension or diabetes. This approach helps in early detection among populations that are more likely to develop the condition, improving resource allocation and targeting high-risk individuals. Multiphasic screening involves testing for multiple diseases or conditions at once, typically using several tests during a single visit. This type of screening is more efficient in terms of time and resources, especially in large populations. It may include screenings for conditions like diabetes, hypertension, and cholesterol levels, all performed simultaneously. Multipurpose screening refers to screening individuals for a variety of health conditions during a single screening event, but the focus is often on addressing different health problems in the same target population. For example, screening a community for a range of chronic diseases such as cardiovascular conditions, diabetes, and cancer in one setting. Opportunistic and case-finding screening occurs when individuals are screened for a condition during a visit for another health problem. It takes advantage of opportunities when patients are already in healthcare settings, such as checking blood pressure or glucose levels during routine checkups. This method is effective for finding cases that may otherwise go unnoticed, especially for chronic conditions.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Multiphasic screening : This involves testing multiple conditions or diseases simultaneously in the general population, often through a series of tests at one time. It is not specifically focused on family members or high-risk groups. Option: B. Mass screening : This refers to screening large populations regardless of their risk status. It aims to detect diseases early in the general population, not focusing on high-risk individuals such as family members of patients with diabetes or hypertension. Option: D. Anonymous screening : This involves screening individuals without requiring personal identifiers, typically used for conditions where confidentiality is paramount, such as in HIV testing. It does not specifically relate to the high-risk screening of family members of individuals with chronic diseases.</p>\n<p><strong>Extraedge:</strong></p><p>Prescriptive Vs Prospective Screening: Prescriptive screening Prospective screening Definition People screened for owns benefits People screened for others benefits Essential purpose Case detection Disease control Request for screening Nonspecific request Special request from authority Eg Neonatal screening Pap smear Urine for sugar Screening of immigrants, HIV screening among sex workers</p>\n<p><strong>Table:</strong></p><p>#MANTRA Types of Screening: Type of Screening Description Target Population Purpose Multiphasic Screening ‚óè       Screening for multiple diseases or conditions during a single visit. ‚óè       General population, often for various conditions. ‚óè       Efficient detection of multiple diseases. Mass Screening ‚óè       Screening the entire population or large groups, regardless of risk. ‚óè       General population. ‚óè       Early detection of high-prevalence diseases. High-risk Screening ‚óè       Screening targeted at individuals with higher risk (e.g., family history). ‚óè       High-risk groups (e.g., family members of patients with chronic diseases). ‚óè       Early detection in those at greater risk. Anonymous Screening ‚óè       Screening where personal identifiers are not used, ensuring confidentiality. ‚óè       Any population, especially for sensitive conditions. ‚óè       Confidential testing for privacy protection.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following groups is not included in the high-risk core population for HIV transmission?", "options": [{"label": "A", "text": "IV drug users", "correct": false}, {"label": "B", "text": "Female sex workers", "correct": false}, {"label": "C", "text": "Men who have sex with men", "correct": false}, {"label": "D", "text": "Long distance truck drivers", "correct": true}], "correct_answer": "D. Long distance truck drivers", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Long distance truck drivers The correct answer is Long distance truck drivers. High-risk core populations for HIV transmission include groups with behaviors that increase the likelihood of exposure, such as IV drug users, female sex workers, and men who have sex with men. These groups are at higher risk due to factors like needle sharing, multiple sexual partners, and unprotected sexual activities. While long distance truck drivers may engage in risky behaviors, they are not generally classified as a core high-risk group for HIV transmission compared to the others.</p>\n<p><strong>Highyeild:</strong></p><p>HIV transmission occurs through several primary routes, with each carrying different risks of transmission depending on the context. Here‚Äôs a breakdown with approximate transmission risks: Sexual Transmission : This is the most common route, with about 80-85% of new HIV infections worldwide occurring through sexual contact. The risk of transmission varies: Unprotected vaginal sex has a risk of about 0.1% to 0.2% per act for women and 0.04% to 0.1% for men. Unprotected anal sex carries a higher risk, especially for receptive anal intercourse, with a transmission risk of about 0.5% to 1% per act. Oral sex has a much lower risk, but it is still possible, especially if there are open sores or bleeding gums. The risk is generally less than 0.04% per act. Needle Sharing (Intravenous Drug Use): The risk of HIV transmission through needle sharing is very high, approximately 0.63% to 1.8% per shared needle. This is due to direct blood-to-blood contact, which facilitates the transfer of the virus. Blood Transfusions: Before screening methods were developed, blood transfusions were a major risk factor for HIV transmission. However, the risk has decreased dramatically with modern screening, now being less than 1 in 2 million units of blood transfused in many countries. Mother-to-Child Transmission (MTCT) : If an HIV-positive mother is not receiving treatment, the risk of transmission to the child during pregnancy, childbirth, or breastfeeding can be as high as 25% to 45%. However, with antiretroviral therapy (ART), the risk can be reduced to less than 1%. Other Routes (Occupational Exposure, Contaminated Medical Instruments): The risk of HIV transmission through occupational exposure (e.g., needlestick injuries) is about 0.3%. The risk through contaminated medical instruments, though rare in countries with proper infection control, can also pose a threat if instruments are not sterilized properly.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. IV drug users : IV drug users are at high risk for HIV transmission because sharing needles can directly transmit the virus, making them one of the highest-risk groups. Option: B. Female sex workers : Female sex workers are also at high risk due to their occupation, which often involves multiple sexual partners and unprotected sex, increasing the likelihood of exposure to HIV. Option: C. Men who have sex with men : Men who have sex with men are at a higher risk for HIV due to higher rates of unprotected sex and the potential for exposure during anal intercourse, which has a higher transmission risk for HIV.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All are live vaccines except:", "options": [{"label": "A", "text": "Rota Virus", "correct": false}, {"label": "B", "text": "Hepatitis B", "correct": true}, {"label": "C", "text": "Measles", "correct": false}, {"label": "D", "text": "Varicella", "correct": false}], "correct_answer": "B. Hepatitis B", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Hepatitis B The Hepatitis B vaccine is not a live vaccine; it is an inactivated (subunit) vaccine made from the recombinant hepatitis B surface antigen. In contrast, Rota Virus, Measles, and Varicella are all live attenuated vaccines, meaning they contain weakened forms of the virus that stimulate the immune system without causing disease. Live vaccines typically require fewer doses, but they are not suitable for individuals with weakened immune systems.</p>\n<p><strong>Highyeild:</strong></p><p>Live Vs Killed Vaccines: Feature Live Vaccines Killed (Inactivated) Vaccines Composition ‚óè       Contain live, weakened forms of the virus or bacteria. ‚óè       Contain killed or inactivated virus or bacteria. Immune Response ‚óè       Stimulate a strong, long-lasting immune response, often with one or two doses. ‚óè       Generally induce a weaker immune response, may require multiple doses. Examples ‚óè       Measles, Mumps, Rubella (MMR), Varicella, Rotavirus, Yellow fever. ‚óè       Hepatitis A, Hepatitis B, Polio (Salk), Influenza (inactivated). Storage ‚óè       May require special storage conditions (e.g., refrigeration or freezing). ‚óè       Generally more stable, can be stored at room temperature or standard refrigeration. Side Effects ‚óè       May cause mild symptoms resembling the disease in rare cases. ‚óè       Less likely to cause side effects, but may require adjuvants to boost the immune response. Safety ‚óè       Safe for most people, but not for those with weakened immune systems (e.g., immunocompromised individuals). ‚óè       Safe for immunocompromised individuals, as they do not contain live organisms. Efficacy ‚óè       Often more effective in providing long-term immunity. ‚óè       May require booster doses for sustained immunity.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Rota Virus : This is a live attenuated vaccine. It contains weakened forms of the rotavirus, which stimulate the immune system to produce immunity without causing disease. Option: C. Measles : This is also a live attenuated vaccine. It contains a weakened form of the measles virus, which replicates in the body to trigger an immune response without causing the disease. Option: D. Varicella : Like the others, the varicella vaccine is a live attenuated vaccine. It contains a weakened form of the varicella-zoster virus, which induces immunity to chickenpox without causing the actual disease.</p>\n<p><strong>Table:</strong></p><p>#MANTRA The Universal Immunization Program (UIP) in India is a comprehensive immunization program implemented by the Government of India to provide vaccination against various preventable diseases. Vaccine Diseases Protected Against Age Group BCG Tuberculosis At birth OPV (Oral Polio Vaccine) Polio Birth, 6 weeks, 10 weeks, 14 weeks, and booster dose at 16-24 months Hepatitis B Hepatitis B Birth, 6 weeks, 10 weeks DTP (Diphtheria, Tetanus, Pertussis) Diphtheria, Tetanus, Pertussis 6 weeks, 10 weeks, 14 weeks, and booster doses at 16-24 months and 5 years Hib (Haemophilus influenzae type b) Haemophilus influenzae type b 6 weeks, 10 weeks, 14 weeks, and booster dose at 16-24 months Rotavirus Rotavirus diarrhea 6 weeks, 10 weeks PCV (Pneumococcal Conjugate Vaccine) Pneumonia, Meningitis 6 weeks, 10 weeks, 14 weeks, and booster dose at 16-24 months Measles Measles 9 months Rubella Rubella 9 months JE (Japanese Encephalitis) Japanese Encephalitis At 9 months in endemic areas DTP Booster Diphtheria, Tetanus, Pertussis 16-24 months OPV Booster Polio 16-24 months Measles-Rubella (MR) Measles, Rubella 16-24 months Td (Tetanus, diphtheria) Tetanus, Diphtheria 5 years TT (Tetanus Toxoid) Tetanus 10 years (for females) HPV (Human Papillomavirus) Cervical Cancer Administered to adolescent girls in 2 doses between 9-14 years</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is not a cold sterilisation technique?", "options": [{"label": "A", "text": "Plasma sterilization", "correct": false}, {"label": "B", "text": "UV radiation", "correct": false}, {"label": "C", "text": "Gamma radiation", "correct": false}, {"label": "D", "text": "Autoclave", "correct": true}], "correct_answer": "D. Autoclave", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Autoclave The autoclave is not a cold sterilization technique; it uses high-pressure steam to sterilize equipment, involving heat. In contrast, plasma sterilization, UV radiation, and gamma radiation are all cold sterilization methods, as they sterilize without the use of heat. Plasma sterilization uses low-temperature plasma, UV radiation utilizes ultraviolet light, and gamma radiation employs ionizing radiation, all effectively sterilizing materials at lower temperatures.</p>\n<p><strong>Highyeild:</strong></p><p>Sterilization is a process that eliminates or kills all forms of microbial life, including bacteria, viruses, fungi, and spores, from a surface or substance. It is an essential procedure in healthcare settings to prevent infections and maintain hygiene standards, particularly for surgical instruments, medical devices, and laboratory equipment. There are two primary categories of sterilization: heat-based and cold or chemical-based methods. Heat-based sterilization includes methods such as autoclaving, which uses high-pressure steam at temperatures of around 121¬∞C to 134¬∞C. This method is effective for most medical tools, as it destroys microorganisms by denaturing their proteins. Another method is dry heat sterilization, which uses hot air at higher temperatures (160¬∞C to 180¬∞C) to destroy pathogens by oxidation. Cold sterilization techniques , on the other hand, do not involve heat. Methods like gamma radiation use ionizing radiation to sterilize items, making it suitable for heat-sensitive materials like plastics. UV radiation sterilizes by damaging the DNA of microorganisms, rendering them incapable of replication. Plasma sterilization employs ionized gas (plasma) at low temperatures, offering a safe alternative for heat-sensitive medical equipment. In addition to these methods, chemical sterilization involves the use of chemical agents, such as ethylene oxide gas or hydrogen peroxide vapor, to sterilize equipment without heat. These chemicals are effective in killing microorganisms but require careful handling due to their toxicity and potential for harmful residues.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Plasma sterilization : This involves the use of low-temperature plasma to sterilize equipment, making it a cold sterilization method. Option: B. UV radiation : Ultraviolet light is used to kill or inactivate microorganisms without the use of heat, making it a cold sterilization technique. Option: C. Gamma radiation : This uses ionizing radiation to sterilize medical equipment and is also considered a cold sterilization method, as it doesn‚Äôt involve high temperatures.</p>\n<p><strong>Extraedge:</strong></p><p>Spaulding‚Äôs Classification:</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "ICER is a unit for which of the following economical analysis?", "options": [{"label": "A", "text": "Cost Effectiveness", "correct": true}, {"label": "B", "text": "Cost Benefit", "correct": false}, {"label": "C", "text": "Cost Utility", "correct": false}, {"label": "D", "text": "Cost Margin", "correct": false}], "correct_answer": "A. Cost Effectiveness", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Cost Effectiveness ICER stands for Incremental Cost-Effectiveness Ratio, which is a key metric used in Cost-Effectiveness Analysis (CEA). It compares the relative costs and outcomes (typically measured in terms of health benefits, such as quality-adjusted life years or life years gained) of different interventions. The ICER is calculated by dividing the difference in cost between two alternatives by the difference in their effectiveness.</p>\n<p><strong>Highyeild:</strong></p><p>Cost-Effectiveness Analysis (CEA) is an economic evaluation method used to compare the costs and health outcomes of different interventions. It is particularly useful in healthcare to assess the value of medical treatments or programs. The results are typically expressed as an Incremental Cost-Effectiveness Ratio (ICER), which calculates the cost per additional unit of health outcome (e.g., quality-adjusted life year or life years gained). CEA allows policymakers to identify the most cost-effective interventions and allocate resources efficiently, especially when resources are limited.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Cost Benefit Analysis (CBA) involves comparing the costs and benefits of an intervention, usually in monetary terms, and does not use ICER. Option: C. Cost Utility Analysis (CUA) is a specific form of CEA that uses utility measures, like Quality-Adjusted Life Years (QALYs), but does not primarily focus on ICER. Option: D. Cost Margin is not a term used in economic evaluations related to healthcare interventions.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Technique Key Characteristics Cost-Benefit Analysis (CBA) ‚óè       Measures both costs and benefits in monetary terms. Allows comparison of projects with different types of outcomes. ‚óè       Often used for large-scale projects or policy decisions. Can be challenging to accurately monetize intangible benefits. Cost-Effectiveness Analysis (CEA) ‚óè       Compares the costs of different interventions to achieve a specific health outcome. Outcomes are measured in natural units (e.g., lives saved, years of life gained). ‚óè       Useful for comparing alternative interventions within a specific disease area. Does not provide information on the overall value of an intervention. Cost-Utility Analysis (CUA) ‚óè       Extends CEA by incorporating quality of life into the analysis. Outcomes are measured in quality-adjusted life years (QALYs). ‚óè       Allows for comparison of interventions with different types of health outcomes. Requires complex methods for assigning QALY weights. Cost-Minimization Analysis (CMA) ‚óè       Identifies the least costly intervention among those with equivalent outcomes. Assumes that the outcomes of the interventions are equally effective. ‚óè       Often used for generic drug substitution or alternative treatment strategies. Limited in scope as it only considers costs.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Universal health coverage (UHC) means that all people and communities receive the quality health services they need, without financial hardship. Which of the following are the challenges to implementing UHC?", "options": [{"label": "A", "text": "Inequalities in the distribution, adequate support and access to quality assured products only in low-income setting", "correct": true}, {"label": "B", "text": "The purpose of UHC is to find a balance between countries